Adaptimmune Therapeutics PLC – (NASDAQ:ADAP)’s share price traded up 5.1% during mid-day trading on Thursday . The company traded as high as $8.62 and last traded at $8.41. 675,877 shares were traded during trading, an increase of 44% from the average session volume of 469,215 shares. The stock had previously closed at $8.00.
A number of equities analysts recently issued reports on the company. BidaskClub cut Adaptimmune Therapeutics from a “sell” rating to a “strong sell” rating in a report on Thursday, March 1st. ValuEngine cut Adaptimmune Therapeutics from a “hold” rating to a “sell” rating in a report on Friday, December 1st. SunTrust Banks reiterated a “buy” rating and issued a $10.00 target price on shares of Adaptimmune Therapeutics in a report on Friday, November 10th. Finally, Zacks Investment Research cut Adaptimmune Therapeutics from a “buy” rating to a “hold” rating in a report on Friday, November 10th. Two equities research analysts have rated the stock with a sell rating, two have assigned a hold rating and three have assigned a buy rating to the company. The stock has a consensus rating of “Hold” and a consensus price target of $11.58.
The company has a market capitalization of $787.91, a price-to-earnings ratio of -11.96 and a beta of 1.79.
ILLEGAL ACTIVITY NOTICE: “Adaptimmune Therapeutics (ADAP) Trading 5.1% Higher” was published by Ticker Report and is owned by of Ticker Report. If you are reading this story on another domain, it was copied illegally and republished in violation of United States & international trademark & copyright legislation. The legal version of this story can be accessed at https://www.tickerreport.com/banking-finance/3254032/adaptimmune-therapeutics-adap-trading-5-1-higher.html.
About Adaptimmune Therapeutics
Adaptimmune Therapeutics plc is a clinical-stage biopharmaceutical company. The Company is focused on cancer immunotherapy products based on its Specific Peptide Enhanced Affinity Receptor (SPEAR) T-cell platform. The Company has developed a platform that enables it to identify cancer targets, find and genetically engineer TCR, and produce TCR therapeutic candidates for administration to patients.
Receive News & Ratings for Adaptimmune Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adaptimmune Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.